Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement

International Journal of Gynecological Pathology

Volumn 26, Issue 1, 2007, Pages 76-82

  Barroeta, Julieta E ^a   Pasha, Theresa L ^a   Acs, Geza ^a   Zhang, Paul J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD10; CD34; Endometrium immunohistochemistry; Stromal cell; Uterine cervix

Indexed keywords

BLOOD CLOTTING FACTOR 13A; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; SMOOTH MUSCLE ACTIN;

ANTIGEN EXPRESSION; ARTICLE; BENIGN UTERUS TUMOR; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; NEPHROBLASTOMA; PRIORITY JOURNAL; STAINING; STROMA CELL; TISSUE SECTION; TUMOR LOCALIZATION; UTERINE CERVIX DYSPLASIA; UTERINE ENDOCERVIX;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; STROMAL CELLS; UTERINE CERVICAL NEOPLASMS;

EID: 33845920011     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000225852.74868.0c     Document Type: Article

References (24)

1. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002;21:11-5.
2. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinomas: an immunohistochemical study. Int J Gynecol Pathol 2002;21:4-10.
3. Kamoi S, AlJuboury MI, Akin MR, et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 2002;21:217-23.
4. McCluggage WG. Recent advances in immunohistochemistry in gynecological pathology. Histopathology 2002;40:309-26.
5. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003;442:271-7.
6. Hendrickson MR, Kempson RL. Normal histology of the uterus and fallopian tubes. In: Sternberg SS, ed. Histology for Pathologists. Philadelphia: Lippincott-Raven Press, 1997:879-927.
7. Silverberg SG, Kurman RJ. Embryology, gross anatomy, and histology. In: Rosai J, ed. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. Washington DC: Armed Forces Institute of Pathology, 1992:1-12.
8. McCluggage WG. A critical appraisal of the value of immunohistochemistry in diagnosis of uterine neoplasms. Adv Anat Pathol 2004;11:162-71.
9. LeBien TW, McCormack RT. The common acute lymphoblastic leukemia antigen (CD10) - emancipation from a functional enigma. Blood 1989;15:625-35.
10. Greaves MF, Hariri G, Newman RA, et al. Selective expression of the common acute lymphoblastic leukaemia (gp100) antigen on immature lymphoid cells and their malignant counterparts. Blood 1983;61:628-39.
11. Pan CC, Chen PC, Ho DM. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology 2004;45:452-9.
12. McCluggage WG, Oliva E, Herrington CS, et al. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial carcinoma. Histopathology 2003;43:144-50.
13. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273-8.
14. Toki T, Shimizu M, Takagi Y, et al. CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol 2001;21:41-7.
15. + fibrocytes in normal cervical stroma, cervical intraepithelial neoplasia III, and invasive squamous cell carcinoma of the cervix uteri. Virchows Arch 2002;441:564-8.
16. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Molec Med 2004;8:498-508.
17. Lindenmayer AE, Miettinen M. Immunophenotypic features of uterine stromal cells. CD34 expression in endocervical stroma. Virchows Arch 1995;426:457-60.
18. Weinberg RA. Tumor suppressor genes. Science 1991;351:453-6.
19. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 2001;264:74-99.
20. Pelletier J, Schalling M, Buckler AJ, et al. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev 1991;5:1345-56.
21. Feingold M, Zilberstein M, Srivastava RK, et al. Expression of Wilms' tumor suppressor gene (WT1) in term human trophoblast: regulation by cyclic adenosine 3, 5-monophosphate. J Clin Endocrinol Metab 1998;83:2503-8.
22. Sumathi VP, Al-Hussaini M, Connoly LE, et al. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody. Int J Gynecol Pathol 2004;23:241-7.
23. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004;23:110-8.
24. Makrigiannakis A, Coukos G, Mantani A, et al. Expression of Wilms' tumor suppressor gene (WT1) in human endometrium: regulation through decidual differentiation. J Clin Endocrinol Metab 2001;86:5964-72.